Anti-GNA13, mouse monoclonal, clone 6F6-B5, recognizes the ~40-45 kDa GNA13 protein in HepG2 cells. It is validated for use in ELISA and Western blotting.
Purified mouse monoclonal antibody. Recognizes the ~40-45 kDa GNA13 protein.
Recognizes the ~40-45 kDa GNA13 protein in HepG2 cells.
Immunogen
Full-length, recombinant, human GNA13 (aa 1-378), expressed as a GST fusion protein
Application
ELISA (see comments) Immunoblotting (1-5 g/ml)
Warning
Toxicity: Regulatory Review (Z)
Physical form
In PBS, pH 7.2.
Reconstitution
Following initial thaw, aliquot and freeze (-20°C).
Analysis Note
Negative Control 293T cells
Positive Control HepG2 cells
Other Notes
For ELISA, this antibody can be used as the capture antibody; recommended concentration is 10 ng/ml, 1 µg/well, 100 µl total volume. Variables associated with assay conditions will dictate the proper working dilution.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Not finding the right product?
Try our Product Selector Tool.
Storage Class Code
12 - Non Combustible Liquids
WGK
nwg
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
The Journal of biological chemistry, 288(11), 7986-7995 (2013-01-19)
G protein-coupled receptors (GPCRs) and their ligands have been implicated in progression and metastasis of several cancers. GPCRs signal through heterotrimeric G proteins, and among the different types of G proteins, GNA12/13 have been most closely linked to tumor progression.
Gα13 (GNA13) is the α subunit of a heterotrimeric G protein that mediates signaling through specific G protein-coupled receptors (GPCRs). Our recent study showed that control of GNA13 expression by specific microRNAs (miRNAs or miRs) is important for prostate cancer
Treatment failure in solid tumors occurs due to the survival of specific subpopulations of cells that possess tumor-initiating (TIC) phenotypes. Studies have implicated G protein-coupled-receptors (GPCRs) in cancer progression and the acquisition of TIC phenotypes. Many of the implicated GPCRs
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
